Alps Group Inc Regains Compliance with Nasdaq Minimum Bid Price Requirement
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Alps Group (Nasdaq: ALPS) regained compliance with Nasdaq’s minimum bid price requirement for continued listing on the Nasdaq Global Market. Nasdaq confirmed that the shares closed with a bid price of at least $1.00 for 10 consecutive business days, from November 9 through November 20, 2026, and closed the matter. The notification did not change trading in the shares.
The ordinary shares began trading on a 1-for-5 post-consolidation basis on November 9. Nasdaq staff had notified Alps on November 16 that the shares were subject to delisting because the company had not met the requirement by the November 11 compliance deadline.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointNasdaq minimum bid price compliance restored after 10 consecutive business days at or above $1.00; Nasdaq closed the matter.
Negative
- None.
Key Figures
- Minimum closing bid price
- $1.00 per share
- Nasdaq continued-listing requirement
- Compliance period
- 10 consecutive business days
- Closing bid was at least $1.00 per share from November 9 to November 20, 2026
- Share consolidation
- 1-for-5
- Ordinary shares began trading on a post-consolidation basis on November 9, 2026
Historical Context
-
Shareholders approved a 1-for-5 consolidation, effective November 9, before the reported compliance period.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
AI-generated analysis. How Rhea-AI works. Not financial advice.
KUALA LUMPUR, Malaysia, Nov. 20, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (“Alps” or “the Company”) (Nasdaq: ALPS), an integrated biotechnology platform headquartered in Malaysia, today announced that it has received written notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Global Market.
On May 19, 2026, the Company previously disclosed that, on May 15, 2026, the Company received a letter from Nasdaq notifying the Company that based on the closing bid price of the ordinary shares of the Company for the prior 30 consecutive business days, the Company was not in compliance with the continued listing requirement of Nasdaq under Nasdaq Listing Rules 5450(a)(1), which requires the Company to maintain a minimum bid price of
On November 9, 2026, the Company’s ordinary shares began trading on a post-consolidation basis following the Company’s previously announced 1-for-5 share consolidation.
On November 16, 2026, the Company received a letter from the Nasdaq Listing Qualifications Staff stating that the Company had not regained compliance with Nasdaq Listing Rule 5450(a)(1), which required the listed ordinary shares to maintain a closing bid price of
On November 20, 2026, the Nasdaq Listing Qualifications Staff notified the Company that the closing bid price of its ordinary shares had been
The notification has no effect on the trading of the Company’s ordinary shares which continue to trade on The Nasdaq Global Market under the symbol “ALPS.”
About Alps Group Inc
Alps Group Inc is a revenue-generating integrated biotechnology platform headquartered in Malaysia, operating across cell manufacturing, molecular diagnostics, and clinical delivery. Alps leverages revenue from its commercial businesses to support its clinical pipeline development, with a mission to make advanced precision medicine accessible and affordable across Southeast Asia.
Forward-Looking Statements
Certain statements in this press release may be considered to contain certain “forward-looking statements” within the meaning of “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “target,” “believe,” “expect,” “will,” “shall,” “may,” “anticipate,” “estimate,” “would,” “positioned,” “future,” “forecast,” “intend,” “plan,” “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on the Company’s management’s current beliefs, expectations, and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of our control. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements.
A further list and description of risks and uncertainties can be found in documents filed with or furnished to the Securities and Exchange Commission (“SEC”) by the Company and other documents that we may file with or furnish to the SEC, which you are encouraged to read. Any forward-looking statement made by us in this press release is based only on information currently available to the Company and speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments, or otherwise, except as required by law.
Investor Relations Contact
Alps Group Inc
Investor Relations
Phone: +60 3-2163 1113
Email: investorrelations@alpsmedical.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.